276
A. Sinopoli et al. / Dyes and Pigments 140 (2017) 269e277
geometries of all complexes were first optimized. TDDFT calcula-
tions on optimized structures in CH3CN by using the COSMO sol-
vation model [57], built in to the NWChem software, were used to
obtain the electronic spectra and molecular orbital energy levels.
Pyba-H). 13C {1H} NMR (400 MHz, CD3CN)
d:166.62, 152.12, 150.38,
149.55, 149.29, 147.27, 139.50, 139.31, 132.83, 132.23, 128.86, 127.98,
127.41, 126.65, 125.21, 125.15, 124.92, 121.6. MS (ESI) m/z calcd for
[C36H24IrN4O4] + 769.142, found 769.2015 (M+).
Synthesis of 4-(2-pyridyl)benzoic acid (pyba)
Synthesis of [Ir(pyba)2(2,5-bis(2-pyridyl)pyrazine)]PF6 (AS11)
The synthetic procedure was the same as that for AS9, except
that 2,5-bis(2-pyridyl)pyrazine (0.043 g, 0.154 mmol), which
replaced 2,2'-bipyridine, was used. The resulting product was pu-
rified and precipitated as for AS9, yielding a dark yellow powder.
This synthetic procedure was adapted from Ref. [58]. Tolyl-
pyridine was oxidized with KMnO4 as follows: a mixture of tolyl-
pyridine (0.514 g) and KMnO4 (1.54 g) in water 50 mL was heated at
70 ꢁC for 24 h. After filtration of the reaction mixture and washing
the filtrate with aqueous NaOH (1M, 5 mL), the combined water
fraction were collected and washed three times with CHCl3 to
remove unconverted starting material. The aqueous solution was
neutralized with HCl (1M) and concentrated (30 mL). After acidi-
fying to pH 4, the precipitate was collected, washed with ethanol
and dried in vacuum yielding a white powder. (Yield 85%) 1H NMR
(28 mg, yield 17.8%) 1H NMR (400 MHz, CD3CN)
d
:9.80 (d, 3J ¼ 8.22,
2H, Dppz-H); 8.51e8.47 (m, 2H, Dppz-H); 8.41 (d, 3J ¼ 4.40, 2H,
Dppz-H); 8.23 (d, 3J ¼ 8.03, 2H, Pyba-H); 8.18e8.14 (m, 2H, Dppz-
H); 8.04e7.90 (m, 6H, Dppz-H&Pyba-H); 7.75 (d, 3J ¼ 8.22, 2H,
Pyba-H); 7.71 (d, 3J ¼ 4.97, 2H, Pyba-H); 7.05 (t, 3J ¼ 6.50, 2H, Pyba-
H); 7.00 (s, 2H, Pyba-H). [Low solubility] 13C {1H} NMR (400 MHz,
CD3CN): 166.05, 152.80, 150.07, 149.61, 148.92, 148.44, 142.80,
139.93, 139.11, 135.38, 132.57, 132.25, 131.34, 129.65, 128.39, 124.77,
124.67, 124.50, 121.16. MS (ESI) calcd for [C42H26IrN6O4]+ 871.1644,
found 871.1631 (M+).
(400 MHz, CD3OD)
d
:8.57 (d, 3J ¼ 4.46, 1H, Py-H); 8.05 (d, 3J ¼ 8.23,
2H, Ar-H); 7.97 (d, 3J ¼ 8.23, 2H, Ar-H); 7.87 (d, 3J ¼ 3.43, 1H, Py-H);
7.37e7.33 (m, 2H, Py-H). 13C {1H} NMR (400 MHz, DMSO-d6):
168.04, 154.59, 148.75, 141.78, 139.90, 131.51, 130.44, 129.98, 127.55,
124.50, 122.69. HRMS (ESI) m/z calcd 199.0633 for C12H9NO2, found
200.0706 (M+H)+
Synthesis of [Ir(pyba)2(4-nitro-2,2'-bipyridine)]PF6 (AS12)
The synthetic procedure was the same as that for AS9, except
that 4-nitro-2,2'-bipyridine (0.031 g, 0.16 mmol), which replaced
2,2'-bipyridine, was used. The resulting product was purified and
precipitated as for AS9, yielding an orange powder. (28.6 mg, yield
Synthesis of [Ir(4-(2-pyridyl)benzoic acid)2Cl]2
353 mg of IrCl3$3H2O (1 mmol) were dissolved in 35 mL 2-
ethoxyethanol:water 3:1 in 2 necked round bottom flask and
degassed with N2 at 80 ꢁC for 20 min 2 equivalents (400 mg) of 4-
(2-pyridyl)benzoic acid were added and heated to reflux temper-
ature for 4 h. The solution was reduced to a minimal volume and
recrystallised from DCM/Hexane. The dimer was used without any
further characterisation or purification.
20%) 1H NMR (400 MHz, CD3CN)
d
:9.81 (d, 3J ¼ 1.88, 1H, Bpy-H);
8.77 (d, 3J ¼ 8.15, 1H, Bpy-H); 8.28 (d, 3J ¼ 5.95, 1H, Bpy-H);
8.26e8.20 (m, 3H, Bpy-H); 8.10 (dd, 3J ¼ 5.95, 4J ¼ 1.88, 1H, Bpy-H);
8.04 (d, 3J ¼ 5.33, 1H, Bpy-H); 8.01e7.92 (m, 4H, Pyba-H); 7.73e7.66
(m, 4H, Pyba-H); 7.60 (t, 3J ¼ 6.42, 1H, Bpy-H); 7.18 (t, 3J ¼ 6.42, 1H,
Pyba-H); 7.16 (t, 3J ¼ 6.58, 1H, Pyba-H); 6.89 (d, 3J ¼ 1.10, 1H, Pyba-
H); 6.85 (d, 3J ¼ 1.10, 1H, Pyba-H). [Low solubility] 13C {1H} NMR
Synthesis of [Ir(pyba)2(2,2'-bipyridine)]PF6 (AS9)
2,2'-bipyridine (0.025 g, 0.16 mmol) was dissolved in
DCM:MeOH 2:1 (6 mL) and [Ir(pyba)2(Cl)]2 (0.100 g, 0.08 mmol)
was added. The mixture was heated at reflux under nitrogen at-
mosphere, in the dark. After 6 h, the yellow solution was cooled to
room temperature. The crude solid was purified by column on silica
eluted with MeCN:H2O:KNO3 7:1:0.5. The yellow fraction was dried
under vacuum, redissolved in acetonitrile and filtered. The solution
was dried again and the solid was dissolved in a minimal amount of
methanol and NH4PF6 (130 mg, 0.9 mmol) was added allowed to
stir overnight. The solution was left in the fridge for two hours,
recrystallised with ether and then filtered on sintered glass. A
yellow powder was collected by filtration. (42 mg, yield 30%) 1H
(400 MHz, CD3CN) d:166.58, 165.90, 165.79, 159.63, 154.78, 154.24,
153.78, 151.35, 149.95, 149.79, 148.16, 148.47, 139.91, 139.33, 139.31,
132.14, 131.90, 130.94, 129.69, 126.13, 124.90, 124.84, 124.79, 124.77,
124.66, 124.58, 121.62, 121.31, 118.27. MS (ESI) calcd for
[C34H23IrN5O6]+ 790.17, found 790.1271 (M+).
Synthesis of [Ir(pyba)2(40,4-dinitro-2,2'-bipyridine)]PF6 (AS13)
The synthetic procedure was the same as that for AS9, except
that 40,4-dinitro-2,2'-bipyridine (0.039 g, 0.16 mmol), which
replaced 2,2'-bipyridine, was used. The resulting product was pu-
rified and precipitated as for AS9, yielding a dark red powder
(40.3 mg, yield 25%) 1H NMR (400 MHz, CD3CN)
d:9.43 (s 2H, Bpy-
NMR (400 MHz, CD3CN)
d
:8.55 (d, 3J ¼ 8.36, 2H, Bpy-H); 8.20 (d, 3J ¼
H); 8.34 (d, 3J ¼ 6.03, 2H, Bpy-H); 8.23 (d, 3J ¼ 8.03, 2H, Pyba-H);
8.18 (dd, 3J ¼ 6.03, 4J ¼ 1.67, 2H, Bpy-H); 8.00 (t, 3J ¼ 8.03, 2H, Pyba-
H); 7.98e7.95 (m, 2H, Pyba-H); 7.73 (d, 3J ¼ 8.03, 2H, Pyba-H); 7.67
(d, 3J ¼ 5.36, 2H, Pyba-H); 7.18 (t, 3J ¼ 6.19, 2H, Pyba-H); 6.85 (s, 2H,
8.36, 2H, Pyba-H); 8.16 (t, 3J ¼ 6.18, 2H, Bpy-H); 8.00e7.94 (m, 4H,
Bpy-H&Pyba-H); 7.93 (d, 3J ¼ 8.36, 2H, Pyba-H); 7.71e7.67 (m, 4H,
Pyba-H); 7.51 (t, 3J ¼ 6.84, 2H, Bpy-H); 7.17 (t, 3J ¼ 6.59, 2H, Pyba-H);
6.89 (s, 2H, Pyba-H).13C {1H} NMR (400 MHz, CD3CN): 167.15,
166.58, 156.29, 151.48, 150.21, 149.79, 149.29, 140.14, 139.61, 132.63,
131.29, 129.10, 125.32, 125.30, 125.26, 124.85, 121.70. MS (ESI) m/z
calcd for [C34H24IrN4O4] + 745.1426, found 745.1427 (M+).
Pyba-H). [Low solubility] 13C {1H} NMR (400 MHz, CD3CN)
d:165.63,
157.76, 157.51, 155.05, 154.17, 154.13, 150.07, 150.04, 139.62, 139.22,
131.92, 131.12, 124.94, 124.92, 122.78, 121.48, 119.56. MS (ESI) m/z
calcd for [C34H22IrN6O8]+ 835.1128, found 835.1135 (M+).
Synthesis of [Ir(pyba)2(1,10-phenanthroline)]PF6 (AS10)
Synthesis of [Ir(pyba)2(N,N'-bis(4-methoxyphenylimino)
acenaphthene)]PF6 (AS14)
The synthetic procedure was the same as that for AS9, except
that 1,10-phenanthroline (0.027 g, 0.16 mmol), which replaced 2,2'-
bipyridine, was used. The resulting product was purified and
precipitated as for AS9, yielding a bright yellow powder. (20 mg,
The synthetic procedure was the same as that for AS9, except
that 4-MeOPh-BIAN (0.063 g, 0.16 mmol), which replaced 2,2'-
bipyridine, was used. The resulting product was purified and
precipitated as for AS9, yielding a brown powder. (35 mg, yield 21%)
yield 13%) 1H NMR (400 MHz, CD3CN)
d
:8.72 (dd, 3J ¼ 8.23, 4J ¼ 1.27,
2H, Phen-H); 8.31 (dd, 3J ¼ 8.5, 4J ¼ 1.27, 2H, Phen-H); 8.26 (s, 2H,
Phen-H); 8.19 (d, 3J ¼ 8.00, 2H, Pyba-H); 7.96 (d, 3J ¼ 8.23, 2H, Pyba-
H); 7.90 (td, 3J ¼ 7.30, 4J ¼ 1.51, 2H, Phen-H); 7.86 (dd, 3J ¼ 8.24, 4J ¼
5.03, 2H, Phen-H); 7.72 (dd, 3J ¼ 8.23, 4J ¼ 1.62, 2H, Pyba-H); 7.51
(dd, 3J ¼ 5.45, 4J ¼ 0.70, 2H, Pyba-H); 7.00 (td, 3J ¼ 5.33, 4J ¼ 1.27, 4H,
1H NMR (400 MHz, CD3CN)
d
: 8.84 (d, 3J ¼ 5.12 Hz, 2H, Pyba -H);
8.31 (d, 3J ¼ 8.28 Hz, 2H, BIAN-H); 8.07e8.01 (m, 4H, Pyba -H); 7.60
(t, 3J ¼ 7.84 Hz, 2H, BIAN-H); 7.52 (d, 3J ¼ 7.68 Hz, 2H, Pyba-H);
7.47e7.41 (m, 4H, Pyba-H); 7.35 (d, 3J ¼ 7.56 Hz, 2H, BIAN-H); 6.99
(bs, 2H, BIAN-H); 6.73 (s, 2H, Pyba-H); 6.63 (bs, 4H, BIAN-H); 6.11